Influence of the COVID-19 pandemic on patients receiving oral anticoagulants for the treatment of non-valvular atrial fibrillation

Josep Comín Colet; Antoni Sicras Mainar; Joel Salazar-Mendiguchía; María Isabel Del Campo Alonso; Ainara Echeto; David Vilanova Larena; Olga Delgado Sánchez

doi:10.1016/j.ijcha.2024.101358

Influence of the COVID-19 pandemic on patients receiving oral anticoagulants for the treatment of non-valvular atrial fibrillation

Int J Cardiol Heart Vasc. 2024 Feb 10:51:101358. doi: 10.1016/j.ijcha.2024.101358. eCollection 2024 Apr.

Authors

Josep Comín Colet¹, Antoni Sicras Mainar², Joel Salazar-Mendiguchía³, María Isabel Del Campo Alonso³, Ainara Echeto³, David Vilanova Larena⁴, Olga Delgado Sánchez⁵

Affiliations

¹ Cardiology Department, Hospital Universitario de Bellvitge (IDIBELL) and CIBERCV, 08907 Hospitalet del Llobregat, Spain.
² Health Economics and Outcomes Research, Atrys Health, 28002 Madrid, Spain.
³ Bristol Myers Squibb, Madrid, Spain, 28050 Madrid, Spain.
⁴ Real World Evidence and Outcomes Research, Bristol Myers Squibb, 28050 Madrid, Spain.
⁵ Pharmacy Department, Hospital Universitario Son Espases, IdISBa, 07120 Palma de Mallorca, Spain.

Abstract

Background: Frequent monitoring of patients declined during the COVID-19 pandemic, harming patients with chronic diseases who critically needed correct monitoring. We evaluated the impact of the COVID-19 pandemic in patients with non-valvular atrial fibrillation (NVAF) receiving treatment with vitamin K antagonists (VKA) or non-vitamin K antagonist oral anticoagulants (NOAC) in clinical practice in Spain.

Methods: This observational, retrospective study analyzed prevalent patients treated with NOAC/VKA on 14/03/2019 (pre-COVID-19 period) and 14/03/2020 (COVID-19 period), who were followed up to 12 months. The study also considered incident patients who started treatment with NOAC/VKA between 15/03/2019 and 13/03/2020 (pre-COVID-19 period) and from 15/03/2020 to 13/03/2021 (COVID-19 period). Demographic characteristics, comorbidities, effectiveness, treatment patterns, and healthcare resource utilization were considered.

Results: Prevalent patients amounted to 12,336 and 13,342 patients, whereas 1,612 and 1,602 incident patients were included in the pre-COVID-19 and COVID-19 periods, respectively. Prevalent patients treated with VKA had more strokes, thromboembolism, and major bleeding compared to those receiving NOAC, particularly during the COVID-19 period. NOAC patients had a 12 % lower risk of death than those on treatment with VKA (Hazard ratio = 0.88 [95 % CI: 0.81 - 0.95], p = 0.033). In addition, VKA patients were less persistent after 12 months than NOAC patients (pre-COVID-19 period: 52.1 % vs. 78.9 %, p < 0.001; COVID-19 period: 49.2 % vs. 80.3 %, p < 0.001), and required more healthcare visits and hospitalizations than those on treatment with NOAC.

Conclusion: Compared to VKA, NOAC seems to have reduced the incidence of severe events and the use of healthcare resources for NVAF, particularly during the pandemic.

Keywords: Anticoagulants; Atrial fibrillation; COVID-19.